跳至主要内容
临床试验/NCT01638273
NCT01638273已完成1 期

A Randomized, Open-label, Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg and Immediate Release Formulation After Multiple Dosing Under Fed Condition in Healthy Male Subjects

GL Pharm Tech Corporation1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2014年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
24
试验地点
1
主要终点
Cmax.ss

研究概览

简要总结

The purpose of this clinical trial is to compare the pharmacokinetic characteristics of GLA5PR GLARS tablet 150mg and Lyrica Capsule 75mg.

GLA5PR GLARS tablet 150mg is a New Formulation which is made by GL Pharm Tech.

GLARS(Geometrically Long Absorption Regulated System) is New Solution to Sustained Absorption by Extending the Absorption Site.

To overcome the shortcomings of the currently existing sustained release drug delivery technologies the investigators have recently developed a novel drug delivery system to enable a drug to be dissolved irrespective of the surrounding environment and further absorbed up to colon. The investigators coined this "Geometrically Long Absorption Regulated System(GLARS)".

详细描述

Basically, this system is a triple-layered tablet, comprised of upper and lower layers that swell and draw a sufficient amount of water, plus a highly water - soluble middle layer that rapidly draw water into the tablet core simultaneously.

The water drawn into the tablet (about 3 to 4 times the weight of the tablet itself) functions as an additional media which enables additional and later drug release out of the dosage form. This serves to overcome the shortage of surrounding media that has been reported to be one of the key reasons for mal-absorption of a drug in colon.

As the middle layer induces a rapid water draw into the tablet core, the penetrated water also diffuses to the upper and lower layers, which makes the tablet to rapidly swell and controls drug release.

At virtually the same time, the swollen upper and lower layers form to surround a lateral side of the middle layer, which can, in turn, further control drug release.

This relatively rigid swollen matrix structure makes drug release not affected by surrounding mechanical flux, which can provide relatively consistent in vivo drug release irrespective of degree of gastrointestinal motility.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 20~45 years old, Healthy Adult Male Subject
  • ≥ 50kg(Body Weight) and Ideal Body Weight ≤ ±20%

排除标准

  • ALT or AST > 1.25(Upper Normal Range)
  • Total Bilirubin > 1.5 (Upper Normal Range)

研究组 & 干预措施

GLA5PR GLARS tablet 150mg(mealed)

Experimental

Pregabalin 150mg

干预措施: Pregabalin 150mg (Drug)

Lyrica Capsule 75mg(mealed)

Active Comparator

Pregabalin 75mg

干预措施: Pregabalin 75mg (Drug)

结局指标

主要结局

Cmax.ss

时间窗: 36hrs

Pharmacokinetic of Pregabalin

AUCtau

时间窗: 36hrs

Pharmacokinetic of Pregabalin

次要结局

  • Safety Monitoring(25 days)
  • Tmax(36hrs)
  • AUC0-∞(36hrs)
  • CL/F(36hrs)
  • Vd/F(36hrs)
  • T1/2(36hrs)

研究者

发起方
GL Pharm Tech Corporation
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

PK Study of Pregabalin GLARS Tablet 150mg and IR... | 临床试验